Clinical Trial Update: The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease [Phase 3]

View source ↗

Summary

The Phase 3 safety and efficacy study of ISU302 for Gaucher disease type 1 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type

Drugs mentioned

• ISU302

Snippet

Sponsor: ISU Abxis Co., Ltd. | Conditions: Gaucher Disease | Phase 3 | Status: WITHDRAWN